Core Insights - Itron reported revenue of $606.76 million for the quarter ended June 2025, a decrease of 0.4% year-over-year, with an EPS of $1.62, up from $1.21 in the same quarter last year [1] - The revenue fell short of the Zacks Consensus Estimate of $609.26 million, resulting in a surprise of -0.41%, while the EPS exceeded the consensus estimate of $1.33 by 21.8% [1] Revenue Breakdown - Device Solutions revenue was $112.76 million, slightly below the average estimate of $113.1 million, reflecting a year-over-year decline of 4.9% [4] - Outcomes revenue reached $85.07 million, compared to the average estimate of $85.73 million, marking a year-over-year increase of 9.3% [4] - Networked Solutions revenue totaled $408.93 million, below the average estimate of $411.45 million, with a year-over-year change of -0.9% [4] Service and Product Revenue - Service Revenue from Networked Solutions was $29.45 million, exceeding the average estimate of $24.94 million, with a year-over-year increase of 16.2% [4] - Total Service Revenue amounted to $89.58 million, surpassing the average estimate of $77.61 million, reflecting a year-over-year growth of 17.6% [4] - Total Product Revenue was $517.18 million, below the average estimate of $531.86 million, indicating a year-over-year decline of 3% [4] Gross Profit and Performance Metrics - Gross Profit for Device Solutions was reported at $33.59 million, exceeding the average estimate of $30.33 million [4] - Itron's shares returned +3.2% over the past month, outperforming the Zacks S&P 500 composite's +2.7% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Financial Performance - Patrick Industries reported $1.05 billion in revenue for the quarter ended June 2025, reflecting a year-over-year increase of 3% [1] - The EPS for the same period was $1.50, compared to $1.44 a year ago, indicating a positive trend in earnings [1] - The revenue reported was a slight miss of -0.01% compared to the Zacks Consensus Estimate of $1.05 billion, while the EPS exceeded the consensus estimate of $1.41 by +6.38% [1] Market Segment Performance - Net Sales in the Recreational Vehicle segment were $479 million, which was below the average estimate of $500.5 million, but showed a year-over-year increase of +6.5% [4] - Net Sales in the Powersports segment were reported at $96 million, falling short of the average estimate of $105 million [4] - Net Sales in the Marine segment reached $156 million, exceeding the average estimate of $133.5 million, but represented a year-over-year decline of -1.1% [4] Stock Performance - Shares of Patrick Industries have returned +2% over the past month, compared to a +2.7% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Core Insights - Cigna reported $67.13 billion in revenue for Q2 2025, an 11% year-over-year increase, with an EPS of $7.20 compared to $6.72 a year ago, exceeding Zacks Consensus Estimates [1] - The revenue surprise was +7.09% over the consensus estimate of $62.69 billion, while the EPS surprise was +0.84% over the consensus estimate of $7.14 [1] Financial Performance Metrics - Medical Care Ratio was 83.2%, matching the average estimate by analysts [4] - Total Medical Customers reached 18.05 million, surpassing the average estimate of 17.92 million [4] - U.S. Healthcare Medical Customers were 16.36 million, slightly above the estimate of 16.23 million [4] - International Health Medical Customers were 1.69 million, in line with the estimate [4] - Net investment income was $236 million, exceeding the average estimate of $219.84 million, but representing a year-over-year decline of 26.5% [4] - Pharmacy revenues were $53.65 billion, significantly above the estimate of $49.16 billion, reflecting a 19% year-over-year increase [4] - Revenues from Evernorth Health Services were $57.83 billion, exceeding the estimate of $54.43 billion, with a year-over-year increase of 16.7% [4] - Evernorth Health Services Pharmacy revenues were $53.99 billion, surpassing the estimate of $51.33 billion, with a year-over-year increase of 16.9% [4] - Cigna Healthcare Premiums revenues were $8.99 billion, slightly above the estimate of $8.87 billion, but showing a year-over-year decline of 21.5% [4] - Total Premiums revenues were $9.16 billion, exceeding the estimate of $8.7 billion, with a year-over-year decline of 20.1% [4] - Fees and Other revenues were $4.14 billion, above the estimate of $4.05 billion, reflecting a year-over-year increase of 13.4% [4] - Cigna Healthcare revenues were $10.8 billion, slightly above the estimate of $10.78 billion, but showing a year-over-year decline of 18.2% [4] Stock Performance - Cigna's shares have returned -7% over the past month, contrasting with the Zacks S&P 500 composite's +2.7% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Insights - Xylem reported revenue of $2.3 billion for the quarter ended June 2025, reflecting a year-over-year increase of 6.1% and surpassing the Zacks Consensus Estimate by 3.93% [1] - The company's EPS for the quarter was $1.26, up from $1.09 in the same quarter last year, exceeding the consensus estimate of $1.14 by 10.53% [1] Revenue Breakdown - Measurement & Control Solutions generated $540 million, exceeding the average estimate of $509.46 million by five analysts, representing a 12% year-over-year increase [4] - Applied Water revenue was $483 million, compared to the estimated $459.4 million, marking a 5.9% increase from the previous year [4] - Water Infrastructure revenue reached $650 million, surpassing the average estimate of $639.53 million, with a year-over-year change of 3% [4] - Water Solutions and Services brought in $628 million, exceeding the average estimate of $605.08 million, reflecting a 4.7% increase year-over-year [4] Adjusted Operating Income - Adjusted Operating Income for Water Infrastructure was $127 million, slightly above the estimate of $124.64 million [4] - Adjusted Operating Income for Applied Water was $94 million, significantly higher than the average estimate of $80.1 million [4] - Adjusted Operating Income for Water Solutions and Services was $106 million, exceeding the estimate of $98.21 million [4] - Corporate and other segments reported an Adjusted Operating Income of -$23 million, worse than the estimate of -$16.4 million [4] - Measurement & Control Solutions had an Adjusted Operating Income of $98 million, surpassing the estimate of $84.05 million [4] Stock Performance - Xylem's shares have returned -0.8% over the past month, while the Zacks S&P 500 composite increased by 2.7% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Core Insights - Bristol Myers Squibb (BMY) reported $12.27 billion in revenue for Q2 2025, a year-over-year increase of 0.6% and a surprise of +7.67% over the Zacks Consensus Estimate of $11.4 billion [1] - The EPS for the same period was $1.46, down from $2.07 a year ago, with a surprise of +36.45% compared to the consensus estimate of $1.07 [1] Revenue Performance - Net sales for Cobenfy were $35 million, exceeding the estimated $28.25 million [4] - Opdivo's U.S. net sales reached $1.51 billion, surpassing the $1.38 billion estimate, reflecting a +7.1% year-over-year change [4] - Pomalyst/Imnovid's U.S. net sales were $584 million, below the $627.82 million estimate, showing an -18.4% year-over-year decline [4] - International net sales for Pomalyst/Imnovid were $124 million, exceeding the $95.34 million estimate, but down -49% year-over-year [4] - Revlimid's net sales were $838 million, above the $625.54 million estimate, representing a -38.1% year-over-year decline [4] - Opdivo's total net sales were $2.56 billion, exceeding the $2.4 billion estimate, with a +7.3% year-over-year increase [4] - Abraxane's net sales were $105 million, slightly above the $102.66 million estimate, but down -54.6% year-over-year [4] - Reblozyl's net sales reached $568 million, surpassing the $546.45 million estimate, with a +33.7% year-over-year increase [4] - Zeposia's net sales were $150 million, exceeding the $129.3 million estimate, but down -0.7% year-over-year [4] - Breyanzi's net sales were $344 million, above the $299.75 million estimate, reflecting a +124.8% year-over-year increase [4] - Abecma's net sales were $87 million, below the $99.76 million estimate, showing an -8.4% year-over-year decline [4] - Opdualag's net sales reached $284 million, exceeding the $276.44 million estimate, with a +20.9% year-over-year increase [4] Stock Performance - Bristol Myers' shares have returned -3.5% over the past month, compared to the Zacks S&P 500 composite's +2.7% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

View all Key Company Metrics for Advanced Micro here>>> The consensus among analysts is that 'Net revenue- Data Center' will reach $3.31 billion. The estimate indicates a year-over-year change of +16.8%. The combined assessment of analysts suggests that 'Net revenue- Embedded' will likely reach $818.30 million. The estimate points to a change of -5% from the year-ago quarter. The consensus estimate for 'Net revenue- Gaming' stands at $750.40 million. The estimate indicates a change of +15.8% from the prior- ...

Core Insights - Conmed reported revenue of $342.35 million for the quarter ended June 2025, reflecting a 3.1% increase year-over-year and a surprise of +0.81% over the Zacks Consensus Estimate of $339.59 million [1] - The company's EPS for the quarter was $1.15, up from $0.98 in the same quarter last year, with an EPS surprise of +1.77% compared to the consensus estimate of $1.13 [1] Revenue Breakdown - Domestic revenue reached $190.6 million, exceeding the average estimate of $186.19 million, marking a year-over-year increase of +2.8% [4] - International revenue was reported at $151.7 million, slightly below the estimated $153.68 million, but still showing a +3.4% increase year-over-year [4] - Net sales in Orthopedic Surgery amounted to $140.7 million, surpassing the average estimate of $139.41 million, with a year-over-year change of +0.9% [4] - Capital Products net sales were $44.5 million, falling short of the $50.63 million estimate, representing a significant year-over-year decline of -15.7% [4] - Single-use Products generated $297.8 million in net sales, exceeding the average estimate of $289.24 million, with a year-over-year increase of +6.6% [4] - General Surgery net sales were reported at $201.6 million, slightly above the estimated $200.46 million, reflecting a +4.7% change compared to the previous year [4] Stock Performance - Conmed's shares have returned -7% over the past month, contrasting with the Zacks S&P 500 composite's +3.4% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Core Insights - PTC Inc. reported revenue of $643.94 million for the quarter ended June 2025, marking a year-over-year increase of 24.2% and exceeding the Zacks Consensus Estimate of $582.4 million by 10.57% [1] - The company's EPS for the same period was $1.64, up from $0.98 a year ago, representing an EPS surprise of 34.43% compared to the consensus estimate of $1.22 [1] Financial Performance Metrics - Annual Recurring Revenue (ARR) was reported at $2.42 billion, surpassing the average estimate of $2.36 billion from three analysts [4] - Recurring Revenue reached $613.58 million, exceeding the four-analyst average estimate of $549.76 million, with a year-over-year change of 27.4% [4] - Professional Services Revenue was $22.59 million, below the average estimate of $28.18 million, reflecting a year-over-year decline of 24.8% [4] - Perpetual License Revenue was reported at $7.76 million, exceeding the average estimate of $6.27 million, with a year-over-year increase of 10.1% [4] Stock Performance - PTC Inc. shares have returned +18% over the past month, significantly outperforming the Zacks S&P 500 composite's +3.4% change [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]

View all Key Company Metrics for Align Technology here>>> Shares of Align Technology have returned +5.9% over the past month versus the Zacks S&P 500 composite's +3.4% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term. Clear Aligner Shipments: 644 versus 672 estimated by two analysts on average. Net revenues- Imaging Systems and CAD/CAM Services: $207.83 million versus the three-analyst average estimate of $205.92 million. The repo ...

本文源自：金融界AI电报 META平台股份有限公司第二季度营收475.2亿美元，同比增长22%，预估448.3亿美元，净利润183.37亿 美元，同比增长36%，经营利润204.4亿美元，同比增长38%，预估172.4亿美元，公司第二季度每股收 益7.14美元，上年同期5.16美元，预估5.89美元。Meta目前预计全年资本支出将在660亿美元至720亿美 元之间，较此前640亿至720亿美元的预期有所提高。 ...